 1. VISEN Pharmaceuticals has obtained the investigational new drug IND approval from the Center for Drug Evaluation CDE of the National Medical Products Administration NMPA for the phase III China clinical trial PaTHway China Trial of TransCon PTH Solution for Injection TransConTM parathyroid hormone. 2. PaTHway China Trial is designed to assess the potential of TransConTM PTH as a hormone replacement therapy, and the aim is to enable patients to have serum calcium sCa within the normal range and independence from usual care. 